Hyphens Pharma prices IPO at S$0.26 a share to raise S$13.5m
The company made a net profit of S$6m in 2017, up 16% from 2016 as revenue rose 12% to S$113m
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
HYPHENS Pharma International, which sells specialty pharmaceutical products, is seeking to raise S$13.5 million in net proceeds ahead of a listing on the Singapore Exchange's (SGX) Catalist board.
Hyphens is offering a total of 29.6 million shares (9.9 per cent of the company) at S$0.26 apiece. Cornerstone investors will take up another 10.1 per cent stake in Hyphens.
Copyright SPH Media. All rights reserved.
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities